BOSTON--(BUSINESS WIRE)--April 26, 2006--Point Therapeutics, Inc. (NASDAQ:POTP - News) presented preclinical data further elucidating talabostat's novel dual mechanism of action during a Company Research and Development Day on April 25, 2006 in New York City. Talabostat is a targeted agent that inhibits dipeptidyl peptidases (DPPs), which are enzymes that regulate biological processes, including tumor growth and immune responses. As a stromal targeted agent, talabostat inhibits fibroblast activation protein (FAP), a DPP that has been shown to contribute to tumor growth. Yesterday, the company also announced that talabostat targets DPP 8 and DPP 9, which have been demonstrated to enhance immune functions in preclinical studies. Talabostat's novel dual mechanism of action introduces a potential new approach for the treatment of cancer.
